Anti-IL-6 receptor [rhPM-1 (Tocilizumab)]

Absolute Antibody

Anti-IL-6 receptor [rhPM-1 (Tocilizumab)]

7

This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958; 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925). The original antibody was used for an in vivo study on ALS. Here they showed that this antibody does not affect all patients the same way. Here it was shown that the antibody lowers inflammation in patients with high inflammation and increases inflammation in patients with low inflammation (Fiala et al., 2013; PMID:23844337). tocilizumab inhibited both the transcription and secretion of cytokines and chemokines induced by apo-G37R. This showed powerful effects on the inflammation in ALS PMBC (Mizwicki et al., 2012; PMID: 23383400)

ELISA, Neutralisation/Blocking

ELISA; inhibit

Research Use Only

Monoclonal

rhPM-1 (Tocilizumab)

IL6R

interleukin 6 receptor

CD126; CD126 antigen; gp80; HIES5; IL-1Ra; IL-6 receptor subunit alpha; IL6Q; IL6QTL; IL-6R; IL-6R-1; IL6RA; IL-6RA; IL6RQ; interleukin-6 receptor subunit alpha; membrane glycoprotein 80

Human

IgG1

Interleukin-6 receptor subunit alpha

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

human

The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.

-20°C,2°C to 8°C

12352203